Table 2.

Prevalence of gram-negative bacteria in SSI wound isolates and proportion testing intermediate or resistant to each antimicrobial.

GRAM-NEGATIVE, n = 39	CTX n = 38	CEFEP n = 39	AMP n = 39	AMOX/CLAV n = 39	GENT n = 39	AMIK n = 39	CIPRO n = 39	LEVOFLOX* n = 30	PIP n = 39	TETRA n = 39	TMP-SMX n = 39	IMI n = 39
Bacteria
E. coli (n = 3)	100	100	100	0	33	0	33	0	0	66	100	0
K. pneumoniae (n = 8)	100	88	100	100	100	0	25	0	75	88	75	0
Proteus. spp (n = 8)	88	88	100	25	13	63	63	67	25	100	63	38
E. cloacae complex (n = 8)	100	100	–	100	75	13	13	0	50	75	88	13
A. baumanii complex (n = 9)	100	78	–	–	56	–	44	0	78	56	67	11
Pseudomonas. spp (n = 2)	–	0	–	–	0	0	0	0	0	0	0	0
S. paucimobilis n = 1)	100	100	–	–	100	100	100	0	100	100	100	0

CTX:ceftriaxone; Cefep:cefepime; Amp:ampicillin; Amox/clav:amoxicillin-clavulanic acid; Gent:gentamicin; Amik:amikacin; Cipro:ciprofloxacin; Levoflox:levofloxacin; Pip:piperacillin-tazobactam; Tetra:tetracycline; TMP-SMX:trimethoprim-sulfamethoxazole; Imi:Imipenem; E. Coli:Escherichia coli; K. pneumoniae:Klebsiella pneumoniae; Proteus spp:Proteus species; E. cloacae complex:Enterobacter cloacae complex; A. baumanii complex:Acinetobacter baumanii complex; Pseudomonas spp:Pseudomonas species; S. Paucimobilis:Sphingomonas paucimobilis. *Antibiotics that were added to the testing panel 3 months into the study, % resistant/intermediate reported in table is based on number of isolates tested. – indicates “Not Tested”. All (n = 30, 100%) isolates tested were resistant to cefazolin and aztreonam. Of 30 isolates tested, 100% were susceptible to ertapenem, one isolate had intermediate susceptibility towards meropenem. Of 30 isolates tested against nitrofurantoin, 100% of K. pneumoniae and Proteus spp., 67% of E. cloacae complex, and 0% of E. coli were intermediate/resistant.